Level C· Early human research exploring benefitsProspective StudyPubMed

Homing of adipose-derived stem cells to radiofrequency catheter ablated canine atrium and differentiation into cardiomyocyte-like cells.

Kim U., Shin DG., Park JS., Kim YJ., Park SI., Moon YM.

Prospective Study on Cardiovascular Disease, published in Int J Cardiol (2009) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int J Cardiol (2009)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
19683815
DOI
10.1016/j.ijcard.2009.07.016
Citations
19

Abstract (original English)

Background and objectives The purpose was to determine whether human adipose-derived stem cells (h-ASCs) can home to the radiofrequency ablated myocardial lesions when injected intravenously and differentiate into cardiomyocyte. Methods Human adipose tissues were obtained from patients and h-ASCs were isolated and cultured. The phenotype of isolated h-ASCs was identified by flow cytometry. Radiofrequency catheter ablation (RFCA) was performed with ten ablation pulses (40 W, 60 s each) to induce heat-mediated lesions at the free walls of the right atria of 14 dogs. Twenty-four hours after ablation, h-ASCs (1 × 10(7) cells) labeled with superparamagnetic iron oxide particles (SPIOs) were infused intravenously in 10 dogs as cell-therapy group and only saline without cells was infused in 4 dogs as control. The hearts were explanted 4 weeks later. Results h-ASCs were identified by flow cytometry as mesenchymal stem cell as positive for CD 13, CD29, CD44, CD90, CD166 and HLA-ABC and immunophenotyping revealed no immunologic responses. SPIO-labeled cells were identified in areas surrounding the RFCA-induced lesions by Prussian blue staining. Immunohistochemistry staining showed positive for anti-α-actinin, anti-cardiac troponin-I, anti-connexin 43 and anti-VEGFR-2. No lymphocyte infiltration, immunorejection or neoplasm-like cells were found in the h-ASC-positive areas. However, multi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAnimalsCatheter AblationCell DifferentiationDogsHeart AtriaHumansMyocytes, CardiacStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research